The company said in a statement that the vaccine “demonstrated 100% protection against moderate and severe disease and 90.4% overall.”
Also, according to the note, “The study was conducted on 29,960 participants at 119 sites in the United States and Mexico to evaluate efficacy, safety, and immunogenicity.”
The company will seek emergency permission to use the vaccine from US health authorities and will do the same in other countries in the third quarter of the year.
The vaccine has been shown to be more than 93% effective against the dominant variants of the coronavirus. The analysis concluded that the variant first identified in the UK, B.1.1.7, was detected in the majority of the cases under study, and that of the Brazil, South Africa, and India variants were also detected among the study participants.
According to officials, the Novavax vaccine did generally well among the participants.
Side effects included headache, fatigue, and muscle pain and were generally mild. A small number of participants experienced serious adverse reactions.
Since the beginning of the epidemic, in March 2020, 17,047 people died in Portugal and 857,447 cases of infection were recorded.
The COVID-19 pandemic has killed at least 3,797,342 people worldwide, resulting in more than 175.5 million infections, according to a balance by AFP.
The disease is transmitted by the new coronavirus, SARS-CoV-2, which was discovered in late 2019 in the central Chinese city of Wuhan.